Most patients have mild skin reactions, while severe (grade 3-4) toxicities are found in a low proportion of patients (5.8% for the ipilimumab + nivolumab combination, even lower values for anti-PD-1 ...

and nivolumab after the radiation. After clinical deterioration within 4 weeks of starting checkpoint therapy, the patient showed a marked increase in T2 changes outside the radiation field.

Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. It can affect arteries, veins, and capillaries. This condition causes blood vessel walls to swell, which ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

Bone-Derived Hormone Predicts Diabetic Kidney Disease Risk Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...

INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the ...

The triplet regimen of cabozantinib, nivolumab, and ipilimumab improved PFS in aRCC patients but did not enhance OS compared to the doublet regimen. Patients receiving the triplet regimen experienced ...